The Prognostic Significance of Vasohibin-1 Expression in Patients with Upper Urinary Tract Urothelial Carcinoma
The Prognostic Significance of Vasohibin-1 Expression in Patients with Upper Urinary Tract Urothelial Carcinoma
复制标题
DOI：
10.1158/1078-0432.ccr-12-0073
复制
发表时间：
2012-08-01
影响因子：
11.5
通讯作者：
Oya, Mototsugu
中科院分区：
文献类型：
--
作者：
Miyazaki, Yasumasa;Kosaka, Takeo;Oya, Mototsugu
目的：Vasohibin-1（VASH 1）是一种新的血管生成分子，其在活化的血管内皮细胞中特异性表达，并且VASH 1的表达状态已在癌症血管生成中被记录。本研究的目的是解决VASH 1表达在上尿路尿路上皮癌（UTUC）的预后价值。实验设计：我们回顾性分析了171例局部晚期UTUC（Ta-3 N 0 M0）患者的临床记录。中位随访期为3.8年。以抗CD 34抗体标记微血管密度（MVD），以VASH 1标记活化内皮细胞标记微血管密度。然后，我们分析了免疫组化表达和临床outcomes.Results之间的关联：42例患者经历了肿瘤复发，其中34例在随访期间死于疾病。VASH 1密度与肿瘤分级、病理T分期和MVD显著相关。VASH 1密度≥ 40/mm 2的患者5年无复发生存率和肿瘤特异性生存率分别为66.1%和72.8%，而VASH 1密度≥ 40/mm 2的患者5年无复发生存率和肿瘤特异性生存率分别为81.0%和86.5%（P < 0.05）。MVD不是肿瘤复发或癌症特异性生存的独立预测因子。多变量分析显示，高VASH 1密度是肿瘤复发（P = 0.024，HR = 2.10）和癌症特异性生存（P = 0.031，HR = 2.23）以及其他标准预后因素，包括高肿瘤分级和淋巴血管浸润的独立预后指标。结果表明，VASH 1密度可能成为一种新的生物标志物，并为UTUC患者提供额外的预后信息。临床癌症研究; 18（15）; 4145-53。（C）2012年AACR。
Purpose: Vasohibin-1 (VASH1) is a novel angiogenic molecule that is specifically expressed in activated vascular endothelial cells, and the status of VASH1 expression has been documented in cancer angiogenesis. The aim of this study was to address the prognostic value of VASH1 expression in upper urinary tract urothelial carcinomas (UTUC).Experimental Design: We retrospectively analyzed the clinical records of 171 patients with locally advanced UTUC (Ta-3N0M0). The median follow-up period was 3.8 years. We immunohistochemically examined the accomplished microvessels with anti-CD34 as microvessel density (MVD) and the microvessels with activated endothelial cells as VASH1 density. Then, we analyzed the association between immunohistochemical expression and clinical outcomes.Results: Forty-two patients experienced tumor recurrence and of these 34 died of the disease during follow-up. VASH1 density was significantly associated with tumor grade, pathologic T stage, and MVD. The 5-year recurrence-free and cancer-specific survival rates were 66.1% and 72.8% in patients with VASH1 density (>= 40/mm(2)) and 81.0% and 86.5% in their counterparts, respectively (P < 0.05). MVD was not an independent predictor of tumor recurrence or cancer-specific survival. Multivariate analyses revealed that high VASH1 density was an independent prognostic indicator of both tumor recurrence (P = 0.024, HR = 2.10) and cancer-specific survival (P = 0.031, HR = 2.23) as well as other standard prognostic factors including high tumor grade and lymphovascular invasion.Conclusions: VASH1 density represents a clinically relevant predictor of patient prognosis in UTUC. The results suggest that VASH1 density could become a new biomarker and provide additional prognostic information in patients with UTUC. Clin Cancer Res; 18(15); 4145-53. (C)2012 AACR.